The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting. In addition, the study will ascertain the baseline VA in treatment -naïve Wet Age-Related Macular Degeneration or neo-vascular AMD (wAMD) patients who start treatment with Aflibercept in a real-life setting and it will assess the impact of baseline VA on the outcomes of Aflibercept treatment.
Study Type
OBSERVATIONAL
Enrollment
2,312
Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Many locations
Lund, Sweden
Change in Visual Acuity (VA) (Snellen)
Change in VA (Snellen) at 3±1 months, 6±1months, 12±2 months and at 24±2 months follow-up in all eyes and stratified in the three groups by Visual Acuity (VA) at baseline.
Time frame: at 3±1 months, 6±1months, 12±2 months and at 24±2 months follow-up
Change in Early Treatment Diabetic Retinopathy Study (ETDRS)
Change Early Treatment Diabetic Retinopathy Study (ETDRS) in all eyes and stratified in the three groups by VA at baseline.
Time frame: at 3±1 months, 6±1months, 12±2 months and at 24±2 months follow-up
Change in Lasbarhetsindex (LIX, Readability Index)
Change in LIX in all eyes and stratified in the three groups by VA at baseline. LIX: Jaeger/LIX adult A chart (Ortho-KM, Lund, Sweden). The LIX-chart is a standardized readability index for measuring near vision and it is used almost ubiquitously in eye clinics in Sweden
Time frame: at 3±1 months, 6±1months, 12±2 months and at 24±2 months follow-up
Proportion of patients with Gain of vision 5 to 15 letters; > 15 letters; Loss of vision >5 to <15 letters; >15 letters or Stable -5 to +5 letters at the annual time points
Patients with Gain of vision 5-15 letters, \> 15 letters; Loss of vision \>5-\<15 letters; \>15 letters or Stable -5-+5 letters at the annual time points
Time frame: At year 1 and year 2
Proportion of patients that recuperate 20/20 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)
In all patients and stratified by baseline VA (groups 1-3)
Time frame: Up to 2 years
Proportion of patients that recuperate 20/40 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
In all patients and stratified by baseline VA (groups 1-3)
Time frame: Up to 2 years
Proportion of patients with no need of Vision Aid support
Time frame: Up to 2 years